OGD Petition
- Vancocin Legal Submision (PDF)
- Vancocin Scientific Submission (PDF)
- Exploratory study in CDAD (PDF)
January 2008 meeting slides and supplemental materials
- ViroPharma slide presentation to OPS/OGD (PDF)
- December 2007 Docket Submission (PDF)
- August 2007 Docket Submission (PDF)
- May 2007 Docket Submission (PDF)
January 2008 letter to OPS (PDF)
July 2008 submission: Comments to Advisory Committee (PDF)
The materials linked from this page contain forward-looking statements that involve risks and uncertainties. Actual results and events may differ significantly from results and events discussed in forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in our Current report on Form 8-K filed with the SEC on January 8, 2008 as well as in the Sections entitled “Risk Factors” of our Annual Report on Form 10-K for the period ended December 31, 2006 and 10Q’s for the period ended March 31, 2007, June 30, 2007 and September 30, 2007 as filed with the Securities and Exchange Commission.